IDH1 and acute myeloid leukemia: In some subsets of AML, molecular diagnostics can suggest the therapies most likely to give a favorable outcome such as expression of cell surface marker CD33 or mutations in specific genes such as FLT3/IDH1/IDH2 (8, 11, 12).